Background-The endocrine balance between atrial natriuretic peptide (ANP) and the renin-angiotensin-aldosterone system is critical for the maintenance of arterial blood pressure and volume homeostasis. This study investigated whether a cardiac imbalance between ANP and aldosterone, toward increased mineralocorticoid receptor (MR) signaling, contributes to adverse left ventricular remodeling in response to pressure overload.
C ompensated hypertensive left ventricular (LV) hypertrophy can progress to adverse remodeling and heart failure (HF) with poor prognosis. Neurohormones play an important role in the complex multiorgan and cellular alterations in HF. Excessive activation of vasoconstricting and proproliferative systems such as the sympathetic and the renin-angiotensin II (Ang II)-aldosterone (RAA) systems has detrimental effects. In particular, cardiac expression and activity of the mineralocorticoid receptor (MR; a ligand-dependent transcription factor) is increased in HF. 1 MR antagonism limits the transition to HF in experimental models of hypertensive or ischemic cardiac remodeling and diminishes morbidity and mortality in patients with severe HF. 2 Although MR is expressed in both cardiac myocytes and fibroblasts, it seems that myocyte MR plays the major pathophysiological role. 3 This is reflected following genetic myocyte-restricted ablation of the MR in mice, which improves ventricular function and remodeling in ischemic or hypertensive HF. 3, 4 In contrast, cardiomyocyte MR overexpression induces arrhythmias 5 and worsens Ang II-induced remodeling. 6 The mechanisms mediating the deleterious effects of cardiomyocyte MR activation remain poorly understood.
the RAA system. 7 They share a cGMP-producing guanylyl cyclase (GC)-A receptor. ANP and BNP, via GC-A, attenuate juxtaglomerular renin as well as adrenal aldosterone release and counteract the vasoconstrictive and antinatriuretic actions of Ang II and aldosterone. Thereby NPs moderate the hypertensive and hypervolemic actions of the RAA system. 7 In addition, experimental and clinical studies indicate that ANP/ BNP exert not only endocrine but also local, cardioprotective actions. Experimentally, overexpression of GC-A in cardiomyocytes attenuated hypertensive or ischemic heart disease. 8 Conversely, conditional, cardiomyocyte-specific inactivation of GC-A exacerbated hypertensive cardiac remodeling. 9 Similar alterations were observed in mice with cardiomyocyte disruption of cGMP-dependent protein kinase I (cGKI), indicating that this kinase is one downstream target mediating the protective actions of NPs in the heart. 10, 11 Consistent with these experimental observations, several approved or investigational treatments of HF enhance intracellular cGMP signaling. 12, 13 Of note, cardiac hypertrophy is accompanied by GC-A desensitization which impairs the systemic and also the local actions of ANP and BNP. [14] [15] [16] As already mentioned, aldosterone levels and MR activity are concomitantly enhanced. 1, 2 Here, we hypothesized that the resulting shift in the local cardiac balance between NPs and aldosterone toward increased MR signaling contributes to the progression from hypertrophy to HF. Accordingly, the goals of this study were (1) to test whether a selective MR antagonist, eplerenone, prevents pressure overload-induced adverse cardiac remodeling in mice with cardiomyocyte-restricted inactivation of the NP/GC-A/ cGKI signaling pathway and (2) to dissect the molecular mechanism(s) favoring adverse hypertensive cardiac remodeling subsequent to a cardiac imbalance between ANP/GC-A (attenuation) and aldosterone/MR (augmentation) signaling.
Methods
Detailed methods are described in the Data Supplement.
Genetic Mouse Models
Mice with cardiomyocyte-restricted deletion of either GC-A (CM GC-A KO) or cGKI (CM cGKI KO) and their respective control littermates (GC-A fl/fl , cGKI fl/fl ) were generated by αMHC-Cre/lox P technology as described previously. 9, 11 All study mice were aged 2 to 3 months. KO and respective control mice were compared in all experiments. The studies complied with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) and were approved by the animal care committee of the University of Würzburg.
Animal Studies
Surgical transverse aortic constriction (TAC, 21 days) or sham operation were performed as described previously. 11 Two weeks before TAC, littermates were randomly assigned to regular chow or chow containing the MR antagonist eplerenone (100 mg/kg body weight per day). Arterial blood pressure was measured in awake mice by tail cuff. 9 Echocardiography was performed under light isoflurane anesthesia before and 3 weeks after TAC. 11 Mice were then euthanized, the LVs, lungs, and tibias were dissected, and LV samples were frozen in liquid nitrogen (for protein or mRNA extraction) or fixed in 4% buffered formaldehyde (for histology and immunohistochemistry). 9, 11 
Histology and Immunohistochemistry
Because dilatative cardiomyopathy is accompanied by increases in myocyte length rather than thickness, we measured the longitudinal instead of cross-sectional areas of single cardiomyocytes. Longitudinal cardiomyocyte areas (length × width) were determined on LV sections stained by diastase-periodic acid Schiff (which stains the sarcolemma) and simultaneously subjected to immunohistochemistry with antibodies directed against pan-cadherin (Cell Signaling, Frankfurt, Germany). This highlighted the intercalated disks and allowed discrimination of longitudinal margins, as previously described. 17 The extent of myocardial fibrosis was determined on sequential LV sections stained with 0.1% picrosirius red. 11 LV expression of connective tissue growth factor (CTGF) protein was examined by immunohistochemistry (antibody from Abcam, Cambridge, United Kingdom). 11
Protein and Gene Expression
Western blotting was performed to analyze LV expression levels of sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a; antibody from Badrilla, Leads, United Kingdom), phosphorylated versus total extracellular regulated kinase 1/2 (ERK1/2), and GAPDH (antibodies from Cell Signaling). LV CTGF mRNA expression levels were quantified by real-time reverse transcription polymerase chain reaction as described recently. 11
Studies in Transfected Human Embryonic Kidney 293 Cells
Because the commercially available anti-MR antibodies were not suitable for immunohistochemical stainings of murine hearts or isolated cardiomyocytes, we studied the expression and interactions of GC-A with MR in overexpressing human embryonic kidney (HEK) 293 cells. As previously described, 15, 18 HEK 293 cells (Invitrogen, Karlsruhe, Germany) stably expressing GC-A, FLAG-tagged GC-A, or cyan fluorescent protein-tagged GC-A were transfected with plasmids encoding for enhanced green fluorescent protein-tagged MR and cGKI with Fugene (Roche, Mannheim, Germany). The cells were maintained in charcoal-stripped (steroid-reduced) medium. For confocal microscopy or fluorescence resonance energy transfer (FRET), 24 hours after transfection, the cells were seeded on coverslips, and the incubation experiments with aldosterone±ANP were performed 24 hours later. For immunoprecipitation studies, the membrane and cytosolic proteins were extracted 48 hours after transfection and the membrane proteins were incubated with anti-FLAG antibody coupled to agarose beads (M2; Sigma, Taufkirchen, Germany) for 2 hours at 4°C under rotation as described before. 15, 18 Aliquots of the cytosolic and membrane fractions and of the immunoprecipitated proteins were subjected to Western blotting with antibodies against MR (DSHB, Iowa), Hsp90 (BD Biosciences, Heidelberg, Germany), cGKI (Cell Signaling), and GC-A. 18 
Statistics
The statistical distribution of the necropsy and histological data sets obtained in the in vivo studies is illustrated with boxes and whisker plots. All other data are expressed as mean±SEM. Data were analyzed by using SPSS. Comparisons between 2 groups were performed using the unpaired Student t test. Cardiac and lung changes in response to TAC and eplerenone were analyzed by nonparametric ANOVA (Kruskal-Wallis test) followed by a Mann-Whitney test to evaluate differences between groups. Repeated-measures ANOVA was used to analyze the echocardiography data, followed by the nonparametric Friedman test. We considered P values <0.05 as statistically significant.
Results

In HEK 293 Cells, ANP Inhibits the Aldosterone-Stimulated Nuclear Translocation of the MR
We investigated whether ANP influences aldosterone-stimulated nuclear translocation of MRs in HEK 293 cells coexpressing GC-A, cGKI, and enhanced green fluorescent protein-tagged MR. The nuclear versus cytoplasmic distributions of fluorescently labeled MRs were analyzed by confocal microscopy. Immunoblotting confirmed the expression of GC-A and cGKI (Figure 1 , inset). Aldosterone (500 pmol/L, 1 hour) induced a marked nuclear accumulation of MRenhanced green fluorescent protein, which was significantly inhibited by ANP (10 nmol/L, pretreatment for 30 minutes; Figure 1 ). Based on these observations, we hypothesized that the local ANP/GC-A system, via cGMP/cGKI signaling, might counter-regulate MR-mediated cardiac actions of aldosterone.
Eplerenone Prevented Adverse LV Remodeling in CM GC-A KO and CM cGKI KO Mice
To directly test the role of the ANP-aldosterone interaction in regulating the cardiac responses to LV pressure overload in vivo, we subjected CM GC-A KO mice or CM cGKI KO mice and respective control littermates to TAC for 21 days in the presence and absence of the selective MR blocker eplerenone. Because the morphological, functional, and molecular responses to TAC were identical in both groups of control mice, these results are combined in all sections and figures throughout the article.
CM GC-A KO and CM cGKI KO mice have normal Mendelian inheritance, grow normally, and have a normal life span. 9, 11 Under resting conditions, their arterial blood pressure as well as cardiac morphology and function are unaltered ( Table I in the Data Supplement) . Also, systolic blood pressure levels in CM GC-A KO, CM cGKI KO, and control mice subjected to TAC were similar (110±2.0, 108±2.8, and 109±2.6 mm Hg, respectively; n=6-10 per group) and were not altered by eplerenone (111±2.0, 107±2.0, and 108±1.8 mm Hg, respectively; n=6-10). As shown in Figure 2A and 2B, TAC in control mice induced only mild but significant increases in LV weight-to-tibia length ratios and myocyte longitudinal areas, and these responses were not influenced by eplerenone treatment. In CM GC-A KO and CM cGKI KO mice, the cardiac hypertrophic responses to TAC were greater than in control mice, as shown at the organ (Figure 2A ) and cellular level ( Figure 2B ). Even more, in both KO strains, TAC also increased the wet lung/tibia length ratios ( Figure 2C ), indicative of pulmonary congestion. In both genotypes, eplerenone significantly attenuated the development of exacerbated LV hypertrophy and fully prevented pulmonary congestion after TAC (Figure 2A-2C ).
Picrosirius red stainings showed mild LV interstitial fibrosis after TAC in both eplerenone-treated and untreated control mice ( Figure 3A) . In contrast, CM GC-A KO and CM cGKI KO mice with TAC developed enhanced LV fibrosis ( Figure 3A ). This was associated with increased expression of the profibrotic cytokine CTGF (quantitated by reverse transcription polymerase chain reaction and corroborated by immunohistochemistry; Figure 3B and 3C). In both genotypes, eplerenone fully prevented pressure overload-induced LV fibrosis and increased levels of CTGF ( Figure 3A-3C ).
Eplerenone Prevented LV Dilatation and Dysfunction in CM GC-A KO and CM cGKI KO Mice
Echocardiography showed that LV contractility did not differ between genotypes under baseline conditions before TAC (Figure 4 ; Table I in the Data Supplement). TAC (with and without eplerenone) did not alter LV geometry or function in control mice (Figure 4 , left column). However, CM GC-A KO and (even more so) CM cGKI KO mice developed severe LV dilatation secondary to TAC, with increases in LV end-diastolic and end-systolic areas and decreased fractional shortening (Figure 4) . Of note, eplerenone fully prevented these morphological and functional alterations. Heart rates in control, CM GC-A KO, or CM cGKI KO mice were similar (574±13, 578±6, and 589±16 beats per minute, respectively; see Table I in the Data Supplement) and were not altered by TAC (562±12, 576±15, and 552±12 beats per minute, respectively) or eplerenone (562±11, 603±6, and 575±8 beats per minute, respectively).
Eplerenone Prevented the Decrease of LV SERCA2a Expression in CM GC-A KO and CM cGKI KO Mice Subjected to TAC
Immunoblot analyses showed that LV SERCA2a protein levels were unaltered in control mice after TAC and were not affected by eplerenone ( Figure 5 ). In contrast, LV SERCA2a expression levels were markedly attenuated in both groups of KO mice 3 weeks after TAC ( Figure 5 ). Notably, this decrease was almost fully prevented by eplerenone treatment ( Figure 5 ). As shown in Figure 5 , TAC provoked significant increases in LV levels of phosphorylated ERK1/2, without differences between genotypes and treatment groups.
Association of Plasma Membrane GC-A and MR Proteins in HEK 293 Cells
Finally, we investigated whether a GC-A/MR colocalization may partly underlie the antagonistic actions of these receptors. For coimmunoprecipitation experiments, MR was transiently coexpressed in HEK 293 cells together with FLAG-tagged GC-A and the membrane proteins were subjected to immunoprecipitation with anti-FLAG (M2) antibody. Western blotting demonstrated that a small fraction of MR is indeed localized at the cell membrane ( Figure 6A ). Even more, membrane MRs coimmunoprecipitate with GC-A, cGKI, and hsp90 ( Figure 6A, right) , indicating that these proteins are part of a complex. MR immunoprecipitation was not obtained in cells transfected with MR and empty vector ( Figure 6A, left) . C, Immunostaining for CTGF. LV myocardium from TAC/untreated KO mice showed diffuse and intensive staining, predominantly in cardiomyocytes, whereas TAC/eplerenone hearts showed reduced stainings for CTGF protein. Similar images were obtained in a total of 5 hearts per group. There was no difference between sham controls and KO mice, and thus one representative sample is shown. 
Single-Cell FRET Analyses Demonstrate That ANP and Aldosterone Modulate the Interaction Between GC-A and MR in HEK 293 Cells
FRET microscopy can be used to monitor protein-protein interactions in intact living cells. Intriguingly, coexpression of cyan fluorescent protein-tagged GC-A and enhanced green fluorescent protein-tagged MR resulted in a substantial basal FRET (baseline ratio green fluorescent protein/cyan fluorescent protein of 0.164±0.002) suggesting close proximity between these receptors. Even more, their ligands, ANP and aldosterone, both induced decreases in FRET by 2% to 3% within 5 to 10 minutes after hormone stimulation ( Figure 6B and 6C) , indicative of an agonist-induced rearrangement within the GC-A/ MR complex. However, pretreatment with ANP (10 minutes) prevented the responses to subsequent application of aldosterone ( Figure 6B and 6C) . These data corroborate the results of the coimmunoprecipitation experiments indicating that GC-A receptors and a subpopulation of membrane MRs interact with each other in a dynamic, hormone-responsive way.
Discussion
Principal Findings
Our observations emphasize that impaired ANP/BNP signaling in cardiomyocytes (here achieved by genetic, cardiomyocyte-restricted GC-A, or cGKI inactivation in mice) does not alter baseline cardiac growth and function, but provokes dilatative cardiomyopathy and pronounced LV interstitial fibrosis in response to pathological pressure overload (induced by TAC). These morphological and functional alterations induced by TAC were associated with enhanced expression of CTGF and diminished expression of SERCA2a. Notably, myocyte hypertrophy was partially attenuated, and LV fibrosis as well as LV contractile dysfunction were almost fully prevented by treatment of the knockout mice with the selective MR blocker eplerenone. MR antagonism also prevented the pressure overload-induced increases in LV CTGF and decreases of SERCA2a expression levels, which may have contributed to the observed improvement in remodeling and LV contractile function. These results provide direct evidence that MRs are involved in mediating pressure overload-evoked HF in mice with selective disruption of cardiac ANP/BNP signaling and indirect evidence for the involvement of aldosterone.
Opposite Effects of ANP/GC-A and Aldosterone/MR Signaling on Myocardial CTGF Expression and Fibrosis
The MRs bind aldosterone and glucocorticoids with similar affinity. 19 The selectivity for aldosterone is achieved by the coexpression of 11β-hydroxysteroid dehydrogenase which inactivates glucocorticoids. 20 The activity of this enzyme is low in cardiomyocytes, and moreover, circulating concentrations of glucocorticoids are much higher than those of aldosterone. 20, 21 Thus, the beneficial effects of MR antagonists in our experimental, as well as in published clinical studies, may partly result from blockade of glucocorticoids binding to cardiomyocyte MR. However, a recent study by Messaoudi et al 22 in mice dissected specific genes regulated by aldosterone in cardiomyocytes and demonstrated that CTGF is induced by aldosterone via the MR, whereas corticosterone had no effect. Conversely, ANP was shown to attenuate CTGF expression and CTGF-dependent fibrosis. 23 In line with these observations, both CM GC-A KO and CM cGKI KO hearts responded to pressure overload with marked induction of CTGF which was totally prevented by eplerenone. Based on these findings, we suggest that ANP, via GC-A/cGKI signaling in cardiomyocytes, counter-regulates the previously established stimulatory effect of aldosterone on myocyte CTGF expression. 22 An imbalance between these systems, favoring aldosterone/MR signaling, enhances myocyte expression of the fibrogenic stimulus CTGF.
Cardiac Imbalance Between GC-A and MR Activities Favors HF After Chronic Pressure Overload
Control mice responded to chronic pressure overload with only mild and functionally well-compensated cardiac hypertrophy. In contrast, both CM GC-A KO and CM cGKI KO mice developed dilatative cardiomyopathy in response to TAC, emphasizing the protective role of local NP signaling. Remarkably, eplerenone treatment had no effect on the adaptive responses of control hearts to pressure overload, but completely prevented LV dilatation and contractile dysfunction in CM GC-A KO and CM cGKI KO mice. This indicates the involvement of enhanced MR signaling in these pathological responses. In line with our observations, mice deficient in cardiomyocyte MR are protected from cardiac dilatation and failure after TAC. 3 The mechanisms by which enhanced MR activity in cardiomyocytes leads to functional deterioration remain unclear. The profibrotic actions of aldosterone might be involved, because myocardial fibrosis can result in excessive muscle fiber entrapment, myocyte atrophy, or abnormal diastolic and systolic stiffness of the myocardium, each of which is sufficient for the development and progression of LV dysfunction. 24 In addition, eplerenone almost fully prevented the pressure overload-dependent reduction of SERCA2a expression in CM GC-A/cGKI KO hearts. Similarly, blockade of the RAA system with angiotensin-converting enzyme inhibitors improved cardiac function in experimental ischemic HF by preventing the depression in SERCA2a expression and activity. 25 Together, these observations suggest that a cardiac imbalance between NP and aldosterone activities impairs myocyte SERCA2a expression and stimulates interstitial fibrosis, both of which may contribute to HF.
NPs, via GC-A, Counter-Regulate Genomic MR Signaling
Nongenomic signaling pathways of the MR, such as the transactivation of the epidermal growth factor receptor and subsequent phosphorylation/activation of the ERK1/2, have also been implicated in the transition to HF. 26, 27 However, although we observed increased LV levels of phosphorylated ERK1/2 in mice subjected to TAC, this response was similar in control and KO mice and was not prevented by eplerenone. Furthermore, mice with cardiomyocyte-restricted MR inactivation did not exhibit diminished cardiac pERK1/2 levels after TAC, 3 indicating that ERK1/2 activation is not linked to MR signaling. Together with the aforementioned CTGF data, these results suggest that classical (genomic) MR signaling pathways participate in adverse cardiac remodeling of CM GC-A/ cGKI KO mice with TAC. This hypothesis is corroborated by the observation that ANP, via GC-A/cGMP, significantly inhibited the aldosterone-stimulated nuclear translocation of the MR in HEK 293 cells (in our study) as well as in colonic epithelial cells. 28 Interestingly, cGMP inhibits the nuclear translocation of another steroid receptor, the vitamin D receptor, in fibroblasts by altering its interaction with the cytoskeletal protein tubulin. 29 Because cGKI can phosphorylate tubulin and microtubule-associated proteins, it was postulated that cGMP prevents dissociation of the activated vitamin D receptor from tubulin. 29 Thus, it is possible that ANP, via cGMP/cGKI, inhibits MR nuclear translocation by altering the interaction of the MR with the cytoskeletal protein transport system. Both the GC-A receptor and the MR have been shown to be associated with the chaperone hsp90. 30, 31 Even more, a small population of MR is cell membrane associated, possibly within cholesterol-rich domains. 26, 32 This population detaches from the membrane in response to aldosterone 26 and might therefore contribute to the genomic actions of the hormone. A subpopulation of GC-A receptors is also localized in caveolae microdomains. 33 Therefore, we postulated that the functional antagonism between GC-A receptors and MRs might be mediated in part by a direct interaction between these proteins. Indeed, coimmunoprecipitation and FRET experiments demonstrated that GC-A and a portion of MRs, cGKI, and hsp90 are within a macromolecular complex at the membrane of HEK 293 cells. Intriguingly, ANP binding to GC-A or aldosterone binding to the MR both caused a conformational change of the MR/GC-A complex (as shown by FRET). Even more, this effect of aldosterone was prevented by ANP pretreatment. Together, these data suggest the existence of a signaling microdomain at the cells membrane which harbors a subpopulation of GC-A receptors and MRs. This interaction might contribute to the moderation of the genomic actions of aldosterone by ANP.
Cardiac Cell Types Mediating the Protective Effects of Eplerenone
Eplerenone antagonizes the MR-mediated effects of aldosterone in different cardiac cell types. Hence, although these studies in CM GC-A/cGKI KO mice were designed to dissect specific cardiomyocyte interactions between NPs and aldosterone, we cannot rule out that the beneficial cardiac effects of eplerenone were mediated in part by other cells such as fibroblasts, endothelial, and inflammatory cells.
Perspectives
In patients with HF, plasma levels of aldosterone, BNP, and (less) ANP are elevated, correlating with the severity of the disease. 1, 34, 35 However, despite these high NP levels, HF is characterized by a combined deficiency of the active form of processed BNP 36 and resistance to both NPs. 7, 14, 16, 18 Because of desensitization of the GC-A receptor, NP-dependent intracellular cGMP formation and subsequent cardiovascular effects are markedly blunted. [14] [15] [16] Of course the mice with genetic cardiomyocyte GC-A or cGKI ablation studied herein present an artificial situation of nonexistent myocyte NP signaling. However, our observations in these mice suggest that a local, cardiac imbalance between the activities of the NP/GC-A (inhibition) and aldosterone/MR systems (augmentation), as occurs in patients with HF, can critically contribute to adverse cardiac remodeling. Our observations support current therapeutic concepts that inhibition of the RAA system combined with augmentation of the natriuretic peptide system (with synthetic analogs or by stabilization of the endogenous hormones with inhibitors of the degrading enzyme neutral endopeptidase) 12, 13 could help to prevent the transition of compensated cardiac hypertrophy to HF.
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